Education and Training
Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a skin condition in which the affected skin becomes painful, red, itchy, and blistered. Dakin's solution may help reduce dermatitis caused by radiation therapy.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Dakin's solution
- radiation: radiation therapy
- other: questionnaire administration
- other: laboratory biomarker analysis
Eligibility
Inclusion Criteria:
- Women with breast cancer who plan to undergo radiation therapy to the breast or chest
wall
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Women with scleroderma or discoid lupus
- Women with inflammatory breast cancer as evidenced by clinical assessment
- Women with breast cancer involving the skin
- Women who have undergone prior radiotherapy to the chest wall and/or breast
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amanda Simmons
650-724-4606
Not Recruiting